Substantial efforts have been put into identifying driven genes such as APC, TP53, PIK3CA, KRAS, SMAD4 and BRAF. Mutations in these genes are involved in the initiation, progression, treatment, drug resistance, prognosis and recurrence of CRC.7, 8, 9, 10. This evidence concerns the gene TP53 and colorectal carcinoma.